Proteomics International Laboratories (ASX:PIQ) subsidiary OxiDx's diagnostic testing technology showed a potential to identify muscle damage and recovery among athletes via a finger prick blood test, according to a Tuesday filing with the Australian bourse.
Based on a study of 20 marathon runners, the OxiDx diagnostic test was able to measure and assess exercise-induced muscle damage, the filing said.
Results were published in the Physiological Reports journal.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.